Immunology CRO Services
Comprehensive evaluation of therapeutic candidates, including immune profiling, safety and efficacy testing, dose optimization, and mechanistic insights with InnoSer’s immunology CRO services
Preclinical Immunology Research with InnoSer
✓ Molecular and Immunology Techniques
✓ Smart Pathological Assessments
✓ Pharmacology Expertise
✓ Validated Models
✓ Tailored Study Designs
✓ Dedicated Research Co-oridnators
As a European preclinical immunology contract research organization (CRO), InnoSer provides you with an integrated immunology portfolio spanning from in vitro to in vivo research services. InnoSer works with well-published in vitro and in vivo models relevant for multiple indications ranging from hypersensitivity, inflammatory, to autoimmune diseases. By choosing InnoSer as your partner CRO, you will work alongside our expert study directors who take a collaborative approach for your study, accommodating your study timelines and budget needs.
InnoSer’s immunology expert team possesses relevant experience in working with multiple therapy types ranging from novel delivery methods, vaccines, small molecules, biologics to cell and gene therapy approaches. Complemented by our pharmacology expertise (such as target validation, biomarker identification, and validation, as well as PK/PD profiling), the InnoSer team works with you to confidently demonstrate the safety and efficacy profile of your novel investigational compound.
Preclinical Immunology Disease Model Catalogue
In Vitro Immuno-assays
Perform initial screening tests using InnoSer’s in vitro immunoassays to select your lead candidate compounds and progress to in vivo studies with confidence
DTH Mouse Model
Evaluate your compound’s immunomodulatory or immunosuppressive potential in the delayed-type hypersensitivity (DTH) mouse model
mRNA/RNA Therapies
Vaccine Testing and mRNA/RNA therapies: LNP delivery, in vitro assays, biodistribution, PKPD, immunogenicity, dose optimization and more
IBD Mouse Models
Test the efficacy of your novel compounds to improve gut health in individuals with IBD through InnoSer’s preclinical expertise and portfolio of IBD mouse models
Diabetes Mouse Model
Test your novel investigational therapy’s effect on glycemic control and glucose tolerance thanks to InnoSer’s expertise in Type 1 diabetes mouse models
EAE Mouse Model
Investigate your compound’s efficacy on the inflammation and immune component of Multiple Sclerosis using the EAE mouse model
IL-23 Induced Psoriasis Mouse Model
Perform quick efficacy tests to evaluate your novel psoriasis treatment strategies using the acute IL-23-Induced Psoriasis Mouse model
Don’t See Your Model? We Can Help!
Our experts specialize in tailored solutions to meet your unique research needs. Let’s discuss how we can support your project.
Immunology Research with InnoSer
Validated research models
As a preclinical immunology CRO, InnoSer performs efficacy studies in well-established and clinically relevant research models. Standardized study protocols ensure consistency and reproducibility of your results. With flexible and fast study start times you can perform your immunology research at an accelerated pace. InnoSer’s expert team continuously works on validating new research models; if you don’t see your research model of choice on our webpage do not hesitate to contact us.
Complemented with molecular and immunology techniques
Carefully designed studies complemented with the most relevant readouts are required to confidently demonstrate your investigational compound’s efficacy. InnoSer offers a wide range of readouts to perform in vitro assays (immune cell activation, immunotoxicity, T-cell activation), cytokine and immune cell profiling (flow cytometry, MSD, ELISA), and biomarker quantification. Additionally, InnoSer works with in-house veterinary pathologists, providing you with accurate and rapid histopathology assessments.
Powered by complementary pharmacology expertise
InnoSer’s immunology CRO services are complemented with pharmacology studies that can be done before or alongside your efficacy studies. Fee-for-service pharmacology studies offered by InnoSer’s team include ADME/ DMPK studies, PK/PD profiling, biodistribution, and early-stage toxicology (dose-response, maximum tolerated dose [MTD], etc.,) studies.
The People Behind Your Research
Céline Erens, PhD, Immunology Study Director
An expert team led by our immunology study director; Céline Erens works together with you to help you set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Frequently Asked Questions
What is a preclinical immunology CRO?
A preclinical immunology contract research organization (CRO) provides specialized research services to support the development and approval of novel immunomodulatory therapeutics. As a preclinical European immunology CRO, InnoSer regularly partners with leading biotechnology and pharmaceutical industry innovators to:
- Offer expert advice and perform a wide range of drug development studies related to pharmacology, early-stage toxicology, and efficacy for various immunomodulatory compound testing.
- Test the therapeutic profile of novel investigational compounds utilizing highly translational in vitro and in vivo models for autoimmune, inflammatory, and hypersensitivity diseases.
- Develop and validate novel models (e.g., humanized mouse models for efficacy testing of various immunomodulatory compounds).
- Partnering with a preclinical immunology CRO like InnoSer provides you with access to cutting-edge resources, accelerates your drug development process, and allows your team to focus on its core objectives without the need for a complex in-house setup.
Contact InnoSer to discuss how we can support your preclinical immunology research goals.
Why should I choose InnoSer as my partner CRO for preclinical immunology research?
- Assess the pharmacologic (e.g., PK/PD, tolerability, dose-response) and toxicologic profile (e.g., maximum tolerated dose) of your compound before moving to efficacy studies
- Demonstrate the efficacy profile of your novel immunomodulatory compounds with our highly translationally relevant in vitro and in vivo models for a range of autoimmune, inflammatory, and hypersensitivity disorders
- Assess immune cell profiling with advanced technologies: obtain valuable insights into modulating cytokine profiles, immune cell recruitment, and immune memory formation using flow cytometry and mesoscale discovery (MSD)
- Track the biodistribution of your compounds in real-time: leverage InnoSer’s expertise in IVIS Imaging and monitor your drug distribution in vivo
- Get expert guidance and real-time study updates: Stay informed with in-life study reports, mid-study data reviews, and a secure data-sharing platform.
What immunology models should I choose for my research?
I don't see my model of choice in your mouse model list, does InnoSer have capabilities to validate new immunology disease models on request?
Yes! At InnoSer, we offer flexible and customizable preclinical immunology CRO solutions, including the development and validation of new immunology research models to meet your specific research needs. If your model of interest is not listed on our website, reach out to our team, who will work together with you to develop and validate novel in vivo and/or in vitro models, ensuring reproducibility and reliability for your preclinical research.
Speak with our immunology experts to discuss your specific study goals.
Stay Curious: More Articles to Explore
Multiplex Cytokine and Immune Cell Profiling in Immuno-Oncology Research
The Meso-Scale Discovery (MSD) platform is a high-sensitivity, multiplex cytokine profiling analysis system, enabling you to simultaneously quantify multiple target cytokines, chemokines, antibodies, and growth factors from minute sample volumes (as low as 1 µL). By...
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com